Point: Combination versus single-agent chemotherapy: The argument for sequential single agents

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 8, 2007, Pages 668-672

  Conlin, Alison K ^a   Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Combination therapy; Metastatic breast cancer; Sequential therapy; Single agent

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LONIDAMINE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; VINBLASTINE;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG DOSE SEQUENCE; HUMAN; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW; SEQUENTIAL ANALYSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 34848923744     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0068     Document Type: Review

References (17)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
2. American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society; 2007.
3. Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005;104:1742-1750.
4. Carrick S, Parker S, Wilcken N, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005;2:CD003372.
5. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17: 1413-1424.
6. Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999;17:2355-2364.
7. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxotubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003;21:588-592.
8. Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998;16:3720-3730.
9. Heidemann E, Stoeger H, Souchon R, et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 2002;13:1717-1729.
10. Norris B, Pritchatd KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group study MA8. J Clin Oncol 2000;18:2385-2394.
11. Ejlettsen B, Mouridsen HT, Langkjer ST, et al. Phase III study of intravenous vinorelbine in combination with epirubicin verus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group trial (SBG9403). J Clin Oncol 2004;22:2313-2320.
12. Berruti A, Bitossi R, Gotzegno G, et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase II study with a factorial design. J Clin Oncol 2002;20:4150-4159.
13. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
14. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival [abstract]. Proc Am Soc Clin Oncol 2004;22:14s(suppl 1 ): Abstract 621.
15. O'Shaughnessy J, Nag S, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study [abstract]. Proc Am Soc Clin Oncol 2003;22(suppl 1): Abstract 25.
16. Fossati R, Confalonieti C, Torri V, et al. Cytotoxic and hormonal treatment for metatstatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439-3460.
17. Miles D, Vukelja S, Moiseyenko V, et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clin Breast Cancer 2004;5:273-278.